Danielle Shand has over 20 years’ experience in the pharmaceutical and medtech sectors, including seven years leading national programs and initiatives that connect industry, research, and Australia’s broader innovation ecosystem.

Prior to joining Biointelect, Danielle held senior leadership roles at MTPConnect, where she led and managed teams to deliver more than $43 million in Medical Research Future Fund (MRFF) investment through the Biomedical Translation Bridge (BTB) and Clinical Translation and Commercialisation (CTCM) Medtech Accelerator programs. She oversaw the strategic planning, governance, and operations of these national initiatives, supporting 33 funded projects, advancing 65 Australian medtech and pharmaceutical technologies, and generating significant follow-on investment across the MTP sector.

Danielle brings expertise in program delivery, governance, grants management, strategic planning, and financial oversight, with 13 years’ earlier experience at Pfizer.

Danielle joined Biointelect in 2026 and is based in Sydney, where she serves as General Manager of Biointelect Venturer. In this role, she leads the strategic design and delivery of the federally funded incubator, supporting emerging companies and academic innovators to advance vaccine and related technologies toward investment and commercial readiness.